MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

1.170 -0.100 (-7.87%)
Official Closing Price Updated: 7:00 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,201,823
Open 1.270
Bid (Size) 1.190 (1,200)
Ask (Size) 1.200 (200)
Prev. Close 1.270
Today's Range 1.160 - 1.280
52wk Range 1.040 - 5.500
Shares Outstanding 20,187,904
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Collaborates With Weave Bio to Support Buntanetap NDA Preparation
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire

Performance

YTD
-67.9%
-67.9%
1 Month
-30.8%
-30.8%
3 Month
-39.4%
-39.4%
6 Month
-48.7%
-48.7%
1 Year
-45.1%
-45.1%

More News

Read More
News headline image
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA ↗
Via MarketBeat
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Host Corporate Update Webinar on Clinical Programs and Milestones
Via Investor Brand Network
News headline image
Annovis to Host Corporate Update Webinar on September 2, 2026
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Promotes Cheng Fang to Chief Scientific Officer
Via Investor Brand Network
News headline image
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
From Annovis Bio Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Regains NYSE Listing Compliance
Via Investor Brand Network
News headline image
Annovis Bio Regains NYSE Listing Compliance
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Prices $15 Million Public Offering of Common Stock and Warrants
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Proposed Public Offering of Common Stock and Warrants
Via Investor Brand Network
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
From Annovis Bio Inc.
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
Via Chartmill
News headline image
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports First-Quarter Progress Across Phase 3 Alzheimer’s and Parkinson’s Programs
Via Investor Brand Network
News headline image
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO to Present Alzheimer’s Multi-Protein Research at Fierce Biotech Week 2026
Via Investor Brand Network
News headline image
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Unusual volume stocks are being observed in Monday's session. ↗
Via Chartmill
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $10 Million Offering To Fund Phase 3 Milestones Through 2027
Via Investor Brand Network
News headline image
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
From Annovis Bio Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Annovis Bio, Inc. Common Stock publicly traded?
Yes, Annovis Bio, Inc. Common Stock is publicly traded.
What exchange does Annovis Bio, Inc. Common Stock trade on?
Annovis Bio, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Annovis Bio, Inc. Common Stock?
The ticker symbol for Annovis Bio, Inc. Common Stock is ANVS on the New York Stock Exchange
What is the current price of Annovis Bio, Inc. Common Stock?
The current price of Annovis Bio, Inc. Common Stock is 1.170
When was Annovis Bio, Inc. Common Stock last traded?
The last trade of Annovis Bio, Inc. Common Stock was at 10/01/26 07:00 PM ET
What is the market capitalization of Annovis Bio, Inc. Common Stock?
The market capitalization of Annovis Bio, Inc. Common Stock is 23.62M
How many shares of Annovis Bio, Inc. Common Stock are outstanding?
Annovis Bio, Inc. Common Stock has 24M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story